Entering text into the input field will update the search result below

Quick-Med Technologies, Inc. (QMDT) Signs New Agreement with Industry Giant BASF

May 20, 2011 2:36 PM ETQMDT
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Quick-Med Technologies, the pioneering life sciences company with an incredibly strong presence for its size in the consumer/healthcare markets via technologies like their FDA-cleared NIMBUS® anti-microbial for wounds and the proprietary MultiStat® anti-aging cosmetic technology, reported today entry into an exclusive worldwide manufacturing and distribution agreement for MultiStat with BASF Corporation, planned to stretch out over multiple years.

BASF Corp. is a unit of the massive chemical company BASF Group, one of the world’s top producers with an impressive network of logistical connections throughout the sector and global markets. BASF Beauty Care Solutions has considerable pull in the cosmetics/beauty care area, with a wide range of proficiencies in the biology of skin aging and is among the world’s top biotech and drug delivery system providers.

This is a huge opportunity for QMDT to bring the MultiStat technology to consumers worldwide through BASF’s supplier infrastructure and this newest agreement will supersede extant agreements between the two companies, providing a cooperative framework all the way up to the end of 2014.

The MultiStat technology is realized via a series of proprietary compounds (Matrix Metalloproteinase Inhibitors) that leverage the breakthrough potential of what is essentially a brand new frontier in anti-aging skin care. These compounds have proven results in a whole range of applications, making the end product extremely attractive for ameliorating the appearance of fine lines and wrinkles associated with skin aging or skin damage associated with getting too much sun.

Specifically, the agreement focus on and covers the compound Ilomastat, which has seen validation as a treatment for maintaining the appearance of young and healthy skin in some 250 or more research studies and published academic work.

CEO of QMDT, J. Ladd Greeno, underscored the value of the new Noctafix ingredient that supercharges “MultiStat’s exciting anti-aging potential”. Noctafix has been shown to offer visible benefits in a consumer perception study that looked at a pool of 49 female panelists, including both smokers and non-smokers. The data showed that skin appeared noticeably healthier and more vibrant as therapy was prolonged, offering statistically validated improvements in the appearance of skin at four, eight and 12 weeks.

For more information on Quick-Med Technologies, please visit their website at: quickmedtech.com

Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.